Kiniksa Pharmaceuticals, Ltd. (KNSA) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 10 Buy.
The consensus price target is $55.67 (low: $50.00, high: $62.00), representing an upside of 18.6% from the current price $46.92.
Analysts estimate Earnings Per Share (EPS) of $-0.39 and revenue of $0.42B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.60 vs est $-0.39 (missed -52.4%). 2025: actual $0.80 vs est $0.97 (missed -17.9%). Analyst accuracy: 72%.
KNSA Stock — 12-Month Price Forecast
$55.67
▲ +18.65% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Kiniksa Pharmaceuticals, Ltd., the average price target is $55.67, with a high forecast of $62.00, and a low forecast of $50.00.
The average price target represents a +18.65% change from the last price of $46.92.
Highest Price Target
$62.00
Average Price Target
$55.67
Lowest Price Target
$50.00
KNSA Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Kiniksa Pharmaceuticals, Ltd. in the past 3 months
EPS Estimates — KNSA
72%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.60
vs Est –$0.39
▼ 34.4% off
2025
Actual $0.80
vs Est $0.97
▼ 21.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — KNSA
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.423B
vs Est $0.424B
▼ 0.2% off
2025
Actual $0.678B
vs Est $0.676B
▲ 0.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
